West Pharma CEO Eric Green to retire after 11 years at the helm | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv- CompaniesWest Pharmaceutical Services IncFollowMarch 9 (Reuters) - West Pharmaceutical's (WST.N), opens new tab chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11- year run at the helm.The Pennsylvania-based company said the transition is expected in the second ...

Oil and gas prices have risen rapidly since the U.S.-Israeli war with Iran began on February 28. The difficulty for stock-market investors is near-term prices are largely dependent on when the Strait of Hormuz substantiallyI am a 35-year stock market investor, MBA, and retired reporter and editor for the San Francisco Chronicle. My primary style is a mix of growth and income, with attention to special situations.Analyst’s Disclosure: I/we have a beneficial long position in the shares of VET, VLO, CVX, CRC e ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2026, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Background - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [4]. - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [4]. - The lawsuit claims that when the true details became known, investors suffered damages [4].

Core Viewpoint - Yalla Group Limited has announced a new share repurchase program authorizing the repurchase of up to US$150 million worth of its outstanding shares over the next 24 months, reflecting the company's confidence in its long-term growth and financial strength [1][1][1] Company Overview - Yalla Group Limited is the largest online social networking and gaming company based in the Middle East and North Africa (MENA), with significant revenues in 2022 [1][1] - The company operates two main mobile applications: Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring popular board games in MENA [1][1] - Yalla has expanded its capabilities in mid-core and hard-core games through its subsidiary, Yalla Game Limited, leveraging local expertise to innovate gaming content [1][1] Financial Strategy - The share repurchase program will be funded using the company's available cash reserves, indicating a strong balance sheet and healthy cash flow [1][1] - The repurchases may occur on the open market or through other legally permissible means, depending on market conditions [1][1] Market Position and Expansion - Yalla is actively exploring opportunities outside of MENA with products like Yalla Parchis, a Ludo game aimed at the South American market [1][1] - The company is focused on creating a regionally integrated ecosystem that meets the evolving online social networking and gaming needs of MENA users [1][1]

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Investor rights law firm Hagens Berman reminds investors in uniQure N.V. (NASDAQ: QURE) that the Lead Plaintiff Deadline in litigation against the company and certain of its executives is rapidly approaching: April 13, 2026. The lawsuit alleges that the defendants made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130, specifically concerning the FDA’s acceptance of a “pivotal” study design that o ...

Core Viewpoint - Dianthus Therapeutics (NASDAQ:DNTH) is a biopharmaceutical company focused on treatments for autoimmune and inflammatory diseases, with a recent price target set at $145 indicating a potential upside of 79.28% from its current price of $80.88 [1][5] Company Performance - The stock has experienced a remarkable 13-fold increase over the past two years, driven by advancements in its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), significantly boosting investor interest [2][5] - Currently, DNTH is priced at $80.68, reflecting a 23.74% increase, or a rise of $15.48, with fluctuations between $78 and $84.86 today, indicating strong investor activity [3][5] - The company has a market capitalization of approximately $2.92 billion and a trading volume of about 2.9 million shares, with the lowest price over the past year being $13.37, showcasing significant growth [4]

Group 1 - Stifel reiterated its Buy rating and $150 price target on Wynn Resorts following recent meetings with the company's Vice President of Investor Relations, Lauren Seiler [1] - The Las Vegas Strip showed a divided performance trend, with higher-end properties, where Wynn specializes, outperforming mid-tier and lower-tier resorts [2] - Wynn likely would have recorded growth in Las Vegas Strip EBITDA this year if not for the ongoing room renovation project at Encore, scheduled to begin in the second quarter of 2026 [2] Group 2 - Wynn has a strong positioning in Macau, where the VIP and premium mass gaming segments have continued to outperform the base mass market [3] - Concerns about margin pressure in Macau exist, but Wynn's fourth-quarter 2025 margins would have been largely unchanged if normalized for hold rates and certain one-time expenses [3] - The recent pullback in Wynn's stock, driven by worries over Macau margin trends and geopolitical concerns tied to the United Arab Emirates, may present a favorable entry point for long-term investors [4]

Chrysler will introduce a refreshed Chrysler Pacifica – America's best-selling and most awarded minivan – reinforcing the brand's long-standing leadership in the segment it invented.For more than 40 years, Chrysler has led the minivan segment, redefining family mobility with advanced safety, available all-wheel drive and the class- exclusive Stow 'n Go seating and storage system. Designed to meet the needs of modern families, the Chrysler Pacifica minivan lineup delivers convenience, capability, and efficie ...

Core Viewpoint - BofA Securities has raised its price target for Scorpio Tankers to $70 from $61 while maintaining an Underperform rating, reflecting a cautious outlook despite recent positive developments in tanker rates [1]. Financial Estimates - The analyst increased first-quarter 2026 earnings estimates by 17% to $2.73 per share and full-year 2026 estimates by 3% to $6.35 per share, driven by a surge in product tanker rates following disruptions in vessel activity due to U.S.–Iran tensions [2]. - The revisions in earnings estimates were made despite Scorpio's sale of three vessels, which reduced its fleet size [2]. Market Conditions - Traffic through the Strait of Hormuz has dropped by over 90%, significantly impacting shipping routes, but historical trends suggest that such disruptions do not lead to prolonged shutdowns [3][4]. - BofA has raised its first-quarter LR2 tanker rate forecast to $47,000 per day from $43,000 per day and increased its MR tanker rate outlook to $27,700 per day from $25,700 per day, indicating a positive shift in market conditions [3]. Valuation Metrics - BofA maintained its Underperform rating while raising its price objective to $70, applying a 6.0x multiple to its 2026 EBITDA estimate, up from 5.25x previously, which still reflects concerns about rising vessel capacity and potential geopolitical changes [5]. - The revised valuation remains below the midpoint of Scorpio's five-year trading range of 4.5x to 8.5x EBITDA, indicating ongoing caution in the market [5].

Core Viewpoint - BofA Securities has lowered its price target for Sea Ltd. to $125 from $150 while maintaining a Buy rating, citing a 30% decline in share price year-to-date due to rising competition in e-commerce and increased investment spending [1] Group 1: E-commerce Segment - Visibility into margin improvement for Sea's e-commerce segment remains limited, as spending levels will heavily depend on competitive dynamics [2] - BofA expects e-commerce EBITDA margins to remain under pressure in the first half of 2026 due to ongoing investments in fulfillment infrastructure, logistics, and customer incentives [3] - Margins at Shopee are anticipated to begin recovering in the second half of 2026 as investments taper following a front-loaded spending cycle [3] Group 2: Other Business Segments - Sea's gaming and fintech segments are maintaining strong momentum, with the fintech unit, Monee, expected to generate higher EBITDA than Shopee despite some margin compression [4] - BofA has not observed significant non-performing asset risks within the fintech portfolio [4] Group 3: Earnings Forecasts and Valuation - BofA has reduced its fiscal 2026–2028 earnings forecasts by 17% to 22% to reflect lower expected margins and higher taxes [5] - The valuation multiple for the e-commerce business has been cut to 20x EBITDA from 30x, citing slower expected profit growth [5] - Despite the lowered price target, BofA argues that consensus estimates have already been significantly reduced, suggesting limited further downside risk following the stock's recent correction [5]